[Endovascular therapy for peripheral arterial disease].
Interventionelle Therapie der peripheren arteriellen Verschlusskrankheit.
Journal
Deutsche medizinische Wochenschrift (1946)
ISSN: 1439-4413
Titre abrégé: Dtsch Med Wochenschr
Pays: Germany
ID NLM: 0006723
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
medline:
23
10
2023
pubmed:
28
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
In addition to conservative therapy with intensive walking training, endovascular revascularisation and open vascular surgical revascularisation are of high importance in the treatment of peripheral arterial disease. Over the past decades, endovascular therapy has developed considerably and is now the treatment of choice for most vascular segments. The use of different devices has been shown to be beneficial for different vessel segments. Primary stent angioplasty has been shown to be superior to balloon angioplasty with secondary stent implantation for the treatment of iliac lesions. Femoropopliteal, the use of paclitaxel-eluting balloon angioplasty is recommended. A mortality signal shown in a meta-analysis was not confirmed. With directional atherectomy and intravascular lithotripsy, different options for plaque modification are available. The cytostatic drug sirolimus as another antirestenotic substance still has to be investigated in large, randomised trials. A final assessment of the effectiveness and safety is not yet possible. Infrapopliteal balloon angioplasty remains the standard treatment. After interventional therapy, regular follow-up is recommended.
Substances chimiques
Coated Materials, Biocompatible
0
Types de publication
English Abstract
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
1301-1306Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
Tanja Böhme: keine Interessenkonflikte. Thomas Zeller: Honorare von: Abbott Vascular, BIBA Medical, Biotronik, Boston Scientific Corp., Cook Medical, Efemoral, Gore & Associates, Medtronic, Philips-Spectranetics, Shockwave, Veryan. Consulted for: Boston Scientific Corp., CSI, Gore & Associates, Medtronic, Veryan, Philips-Intact Vascular, Shockwave, Bayer, Vesper Medical, VentureMed, ANT. Institutionelle Zuschüsse für Forschung, klinische Studien oder Arzneimittelstudien von: Bard Peripheral Vascular, Veryan, Biotronik, Cook Medical, Gore & Associates, Medtronic, Philips, Terumo, TriReme, Shockwave, Med Alliance, Intact Vascular, B. Braun; CSI, Boston Scientific, University of Jena, Pluristem, Philips, PQ Bypass, Surmodics, Alative Solutions, Reflow Medical